Home LiteratureArticle Details
PMID: 15452286 Published · ppublish English Journal Article Multicenter Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Motor signs during the course of Alzheimer disease.

Neurology ·Vol. 63 ·No. 6 ·2004-09-28 ·Pages 975-82

Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, Dubois B, Sarazin M, Brandt J, Albert M, Marder K, Bell K, Honig LS, Wegesin D, Stern Y

Abstract

Motor signs (MOSIs) are common in Alzheimer disease (AD) and may be associated with rates of cognitive decline, mortality, and cost of care. To describe the progression and identify predictors of individual MOSIs in AD. A cohort of 474 patients with AD at early stages was followed semiannually for up to 13.1 years (mean 3.6 years) in five centers in Europe and the United States. MOSIs were rated using a standardized portion of the Unified Parkinson's Disease Rating Scale. Overall, 3,030 visits/assessments of MOSIs (average 6.4/patient) were performed. Prevalence and incidence rates were calculated, and cumulative risk graphs were plotted for individual non-drug-induced MOSI domains. Rates of change over time taking into account potential covariates were also estimated. With use of each MOSI domain as outcome in Cox models, predictors of MOSI incidence were identified. At least one MOSI was detected in 13% of patients at first examination and in 36% for the last evaluation. Total MOSI score increased at an annual rate of 3% of total possible score. Rates of annual change for speech/facial expression (4%), rigidity (2.45%), posture/gait (3.9%), and bradykinesia (3.75%) were of similar magnitude, and their occurrence increased from first (3 to 6%) to last (22 to 29%) evaluation. Tremor was less frequent throughout the course of the disease (4% at first and 7% at last evaluation) and worsened less (0.75% increase/year). Most motor signs occur frequently and progress rapidly in Alzheimer disease. Tremor is an exception in that it occurs less frequently and advances at slower rates.

MeSH Terms
Aged Aged, 80 and over Alzheimer Disease/complications,economics,genetics,physiopathology Apolipoproteins E/genetics Basal Ganglia Diseases/epidemiology,etiology,physiopathology Cohort Studies Disease Progression Europe/epidemiology Extrapyramidal Tracts/physiopathology Facial Expression Female Follow-Up Studies Humans Hypokinesia/epidemiology,etiology Incidence Male Middle Aged Movement Disorders/economics,epidemiology,etiology Prevalence Proportional Hazards Models Severity of Illness Index Tremor/epidemiology,etiology United States/epidemiology
Chemicals
Apolipoproteins E
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Scarmeas N
Cognitive Neuroscience Division, Taub Institute for Research in Alzheimer's Disease and the Aging Brain, Gertrude H. Sergievsky Center, and Department of Neurology, New York, NY 10032, USA. ns257@columbia.edu
Hadjigeorgiou G M
Papadimitriou A
Dubois B
Sarazin M
Brandt J
Albert M
Marder K
Bell K
Honig L S
Wegesin D
Stern Y
References (42)
42 references, click to expand
  1. Progression of parkinsonian signs in Alzheimer's disease.
    Neurology. 2000 Mar 28;54(6):1284-9 PMID: 10746599
  2. Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX.
    Neurology. 1999 Jun 10;52(9):1839-44 PMID: 10371532
  3. An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease.
    Arch Neurol. 2001 Mar;58(3):460-5 PMID: 11255450
  4. Effect of extrapyramidal signs and Lewy bodies on survival in patients with Alzheimer disease.
    Arch Neurol. 2002 Apr;59(4):588-93 PMID: 11939893
  5. Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease.
    Neurology. 2002 Apr 23;58(8):1182-8 PMID: 11971084
  6. Apolipoprotein E epsilon 4 in an autopsy series of various dementing disorders.
    J Alzheimers Dis. 2003 Apr;5(2):119-25 PMID: 12719629
  7. The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies.
    Neurology. 2003 Oct 14;61(7):944-9 PMID: 14557565
  8. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.
    Br J Psychiatry. 1968 Jul;114(512):797-811 PMID: 5662937
  9. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
    J Psychiatr Res. 1975 Nov;12(3):189-98 PMID: 1202204
  10. Depression, intellectual impairment, and Parkinson disease.
    Neurology. 1981 Jun;31(6):645-50 PMID: 7195481
  11. Striatal dopamine receptors in Alzheimer-type dementia.
    Neurosci Lett. 1984 Nov 23;52(1-2):1-6 PMID: 6241300
  12. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients.
    Neurology. 1987 May;37(5):754-60 PMID: 3033544
  13. Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease.
    Neurobiol Aging. 1988 May-Jun;9(3):245-52 PMID: 3398991
  14. Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases.
    Ann Neurol. 1988 Jul;24(1):50-6 PMID: 3415200
  15. Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors?
    Arch Neurol. 1989 Jun;46(6):651-7 PMID: 2730377
  16. The prognosis in Alzheimer's disease. 'How far' rather than 'how fast' best predicts the course.
    Arch Neurol. 1990 Aug;47(8):851-6 PMID: 2375690
  17. Clinical and positron emission tomographic studies in the 'extrapyramidal syndrome' of dementia of the Alzheimer type.
    Arch Neurol. 1990 Dec;47(12):1318-23 PMID: 2252449
  18. Neurological signs in Alzheimer's disease.
    Age Ageing. 1991 Jan;20(1):45-51 PMID: 2028851
  19. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group.
    Arterioscler Thromb. 1991 Sep-Oct;11(5):1237-44 PMID: 1680392
  20. Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer's disease.
    Arch Neurol. 1991 Nov;48(11):1141-3 PMID: 1953398
  21. Interrater reliability of extrapyramidal signs in a group assessed for dementia.
    Arch Neurol. 1991 Nov;48(11):1147-9 PMID: 1953399
  22. Cognitive decline in patients with Alzheimer disease: differences in patients with and without extrapyramidal signs.
    Alzheimer Dis Assoc Disord. 1991 Winter;5(4):251-6 PMID: 1781967
  23. Extrapyramidal signs in Alzheimer's disease: a 3-year follow-up study.
    J Neural Transm Park Dis Dement Sect. 1992;4(2):107-19 PMID: 1349210
  24. Operational criteria for senile dementia of Lewy body type (SDLT).
    Psychol Med. 1992 Nov;22(4):911-22 PMID: 1362617
  25. Multicenter study of predictors of disease course in Alzheimer disease (the "predictors study"). I. Study design, cohort description, and intersite comparisons.
    Alzheimer Dis Assoc Disord. 1993 Spring;7(1):3-21 PMID: 8481224
  26. 'How far' vs 'how fast' in Alzheimer's disease. The question revisited.
    Arch Neurol. 1994 Mar;51(3):275-9 PMID: 8129639
  27. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease.
    Arch Neurol. 1994 Jul;51(7):676-81 PMID: 8018040
  28. Apolipoprotein-E epsilon-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease.
    Neurosci Lett. 1994 Nov 21;182(1):63-5 PMID: 7891889
  29. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
    Ann Neurol. 1995 Mar;37(3):300-12 PMID: 7695230
  30. Study of Alzheimer's dementia patients with parkinsonian features.
    J Geriatr Psychiatry Neurol. 1995 Jul;8(3):154-8 PMID: 7576038
  31. Comorbidity and its effect on mortality in nursing home patients with dementia.
    J Nerv Ment Dis. 1996 Mar;184(3):180-7 PMID: 8600222
  32. Clinical features and mortality in patients with early-onset Alzheimer's disease.
    Eur Neurol. 1996;36(2):103-6 PMID: 8654478
  33. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant.
    Neurology. 1996 Jul;47(1):190-6 PMID: 8710076
  34. Extrapyramidal motor signs in clinically diagnosed Alzheimer disease.
    Alzheimer Dis Assoc Disord. 1996 Summer;10(2):103-14 PMID: 8727172
  35. Alzheimer's disease and its Lewy body variant: a clinical analysis of postmortem verified cases.
    Am J Psychiatry. 1996 Oct;153(10):1269-73 PMID: 8831433
  36. Pathological correlates of extrapyramidal signs in Alzheimer's disease.
    Ann Neurol. 1997 Mar;41(3):368-74 PMID: 9066358
  37. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease.
    Ann Neurol. 1997 May;41(5):615-20 PMID: 9153523
  38. Extrapyramidal signs in patients with probable Alzheimer disease.
    Arch Neurol. 1997 Aug;54(8):969-75 PMID: 9267971
  39. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale.
    Neurology. 1997 Dec;49(6):1580-7 PMID: 9409350
  40. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease.
    Neurology. 1998 Aug;51(2):351-7 PMID: 9710002
  41. Progression of parkinsonian signs in Parkinson disease.
    Arch Neurol. 1999 Mar;56(3):334-7 PMID: 10190824
  42. The association between parkinsonism, Alzheimer's disease, and mortality: a comprehensive approach.
    J Am Geriatr Soc. 2000 Apr;48(4):422-5 PMID: 10798470
Article Info
Journal
Neurology
Abbr.
Neurology
ISSN
1526-632X
Published
2004-09-28
Pages
975-82
Language
English
Region
United States
NLM ID
0401060
PMCID
PMC3028531
Subset
IM
Grants
NCRR NIH HHS · RR00645 · United States
NIA NIH HHS · R01 AG007370-07 · United States
NIA NIH HHS · R01 AG007370 · United States
NCRR NIH HHS · M01 RR000645 · United States
Intramural NIH HHS · Z01 AG007370 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com